Sugi Predict

Sugi Predict / Targets / GSKIP

GSKIP

GSK3B-interacting protein · Q9P0R6 · GSKIP on Sugi Atlas →

0 patent compounds predicted against GSKIP, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to GSKIP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Lithium As a Treatment to Prevent Impairment of Cognition in Elders PHASE4COMPLETED
Lithium in Acute Kidney Injury PHASE4UNKNOWN
Lithium for Prevention of Cognitive Declining in Mood Illnesses PHASE4NOT_YET_RECRUITING
Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation PHASE4COMPLETED
The Neurotrophic Effects of Lithium Carbonate Following Stroke: A Feasibility Study PHASE3COMPLETED
9-ING-41 in Patients With Advanced Cancers PHASE2ACTIVE_NOT_RECRUITING
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma PHASE2WITHDRAWN
A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration PHASE1/PHASE2COMPLETED
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer PHASE2ACTIVE_NOT_RECRUITING
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy PHASE2RECRUITING
A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria PHASE2NOT_YET_RECRUITING
Phase II Study Evaluating the Safety and Efficacy of GSK315234A in Patients With Rheumatoid Arthritis PHASE2COMPLETED
A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy PHASE2COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis PHASE2COMPLETED
A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB) PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults PHASE2COMPLETED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. PHASE1COMPLETED
GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers PHASE1COMPLETED
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma PHASE1WITHDRAWN
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants PHASE1COMPLETED
Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects PHASE1COMPLETED
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults. PHASE1COMPLETED
A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA) PHASE1COMPLETED
Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Evaluation of Lithium as a Glycogen-Synthase-Kinase-3 (GSK-3) Inhibitor in Mild Cognitive Impairment nanCOMPLETED
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Precision-Based Genomics in Prostate Cancer nanRECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GSKIP binder may also engage these)

ProteinNameSimilarity
Q4R812 — 1.000 Q4R812 →
Q5ZMC6 — 1.000 Q5ZMC6 →
Q5PPI3 — 1.000 Q5PPI3 →
Q0P5A3 — 0.999 Q0P5A3 →
Q8BGR8 — 0.998 Q8BGR8 →
Q7ZWI4 — 0.997 Q7ZWI4 →
A4IIW5 — 0.994 A4IIW5 →
Q9V8F3 — 0.993 Q9V8F3 →
F4IDQ6 — 0.986 F4IDQ6 →
Q6C710 — 0.985 Q6C710 →
Q9UUJ7 — 0.985 Q9UUJ7 →
Q8STE5 — 0.985 Q8STE5 →
O76240 — 0.984 O76240 →
Q8T1E3 — 0.984 Q8T1E3 →
Q61T02 — 0.984 Q61T02 →
Q9STV0 — 0.984 Q9STV0 →
Q8T913 — 0.984 Q8T913 →
Q9M548 — 0.984 Q9M548 →
P87117 — 0.984 P87117 →
KDM5B Lysine-specific demethylase 5B 0.984 landscape →
SEPTIN8 Septin-8 0.984 landscape →
O94443 — 0.984 O94443 →
Q9P7R4 — 0.984 Q9P7R4 →
Q9HDW4 — 0.984 Q9HDW4 →
Q04638 — 0.984 Q04638 →
O14045 — 0.983 O14045 →
Q5XI06 — 0.983 Q5XI06 →
O43035 — 0.983 O43035 →
Q5XI69 — 0.983 Q5XI69 →
Q9VTT9 — 0.983 Q9VTT9 →